{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:52:27Z","timestamp":1772214747666,"version":"3.50.1"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","award":["APP1141445"],"award-info":[{"award-number":["APP1141445"]}],"id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1196605"],"award-info":[{"award-number":["APP1196605"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009321","name":"icare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016233","name":"Simon Lee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Mesothelioma is characterised by its aggressive invasive behaviour, affecting the surrounding tissues of the pleura or peritoneum. We compared an invasive pleural model with a non-invasive subcutaneous model of mesothelioma and performed transcriptomic analyses on the tumour samples. Invasive pleural tumours were characterised by a transcriptomic signature enriched for genes associated with MEF2C and MYOCD signaling, muscle differentiation and myogenesis. Further analysis using the CMap and LINCS databases identified geldanamycin as a potential antagonist of this signature, so we evaluated its potential\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Nanomolar concentrations of geldanamycin significantly reduced cell growth, invasion, and migration\n                    <jats:italic>in vitro<\/jats:italic>\n                    . However, administration of geldanamycin\n                    <jats:italic>in vivo<\/jats:italic>\n                    did not result in significant anti-cancer activity. Our findings show that myogenesis and muscle differentiation pathways are upregulated in pleural mesothelioma which may be related to the invasive behaviour. However, geldanamycin as a single agent does not appear to be a viable treatment for mesothelioma.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0274364","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T13:23:45Z","timestamp":1683293025000},"page":"e0274364","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-0873","authenticated-orcid":true,"given":"M. Lizeth","family":"Orozco Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally M.","family":"Lansley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. C. Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-6163","authenticated-orcid":true,"given":"Rachael M.","family":"Zemek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Joost","family":"Lesterhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"11","key":"pone.0274364.ref001","first-page":"1","article-title":"Malignant peritoneal mesothelioma: A review","volume":"5","author":"J Kim","year":"2017","journal-title":"Ann Transl Med"},{"issue":"142","key":"pone.0274364.ref002","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment","volume":"25","author":"AC Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"15","key":"pone.0274364.ref003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in Malignant Mesothelioma","volume":"353","author":"BWS Robinson","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0274364.ref004","first-page":"1117","article-title":"Plasticity of tumor cell invasion: Governance by growth factors and cytokines","volume":"37","author":"J Odenthal","year":"2016","journal-title":"Carcinogenesis"},{"issue":"5","key":"pone.0274364.ref005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.cell.2011.11.016","article-title":"Cancer invasion and the microenvironment: Plasticity and reciprocity","volume":"147","author":"P Friedl","year":"2011","journal-title":"Cell"},{"issue":"14","key":"pone.0274364.ref006","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10272","key":"pone.0274364.ref007","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"pone.0274364.ref008","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"AK Nowak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0274364.ref009","first-page":"1","article-title":"Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial","volume":"12","author":"PS Kok","year":"2022","journal-title":"BMJ Open"},{"issue":"7\u20138","key":"pone.0274364.ref010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","article-title":"Transcriptional data: A new gateway to drug repositioning?","volume":"18","author":"F Iorio","year":"2013","journal-title":"Drug Discov Today"},{"issue":"5795","key":"pone.0274364.ref011","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease","volume":"313","author":"J Lamb","year":"2006","journal-title":"Science (80-)"},{"issue":"16015","key":"pone.0274364.ref012","first-page":"1","article-title":"L1000CDS2: LINCS L1000 characteristic direction signatures search engine","volume":"2","author":"Q Duan","year":"2016","journal-title":"npj Syst Biol Appl"},{"issue":"4","key":"pone.0274364.ref013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2013.1","article-title":"Computational drug repositioning: From data to therapeutics","volume":"93","author":"MR Hurle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pone.0274364.ref014","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.isci.2021.103571","article-title":"PPAR\u03b1 and PPAR\u03b3 activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective","volume":"25","author":"ML Orozco Morales","year":"2022","journal-title":"iScience"},{"issue":"550","key":"pone.0274364.ref015","first-page":"1","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI Love","year":"2014","journal-title":"Genome Biol"},{"issue":"4","key":"pone.0274364.ref016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"A Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"pone.0274364.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-015-0031-0","article-title":"Myocyte enhancer factor 2C function in skeletal muscle is required for normal growth and glucose metabolism in mice","volume":"5","author":"CM Anderson","year":"2015","journal-title":"Skelet Muscle"},{"key":"pone.0274364.ref018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.abb.2013.12.015","article-title":"Myocardin and smooth muscle differentiation","volume":"543","author":"XL Zheng","year":"2014","journal-title":"Arch Biochem Biophys"},{"issue":"218","key":"pone.0274364.ref019","article-title":"InnateDB: Facilitating systems-level analyses of the mammalian innate immune response","volume":"4","author":"DJ Lynn","year":"2008","journal-title":"Mol Syst Biol"},{"issue":"3","key":"pone.0274364.ref020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"VK Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"43","key":"pone.0274364.ref021","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0274364.ref022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene Ontology: tool for the unification of biology","volume":"25","author":"M Ashburner","year":"2000","journal-title":"Nat Genet"},{"issue":"6","key":"pone.0274364.ref023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"A Liberzon","year":"2016","journal-title":"Cell Syst"},{"key":"pone.0274364.ref024","article-title":"Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"EY Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"pone.0274364.ref025","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"M V. Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"pone.0274364.ref026","first-page":"1","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Z Xie","year":"2021","journal-title":"Curr Protoc"},{"issue":"18","key":"pone.0274364.ref027","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60(v-src) heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation","volume":"91","author":"L Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pone.0274364.ref028","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1006382320697","article-title":"Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity","volume":"17","author":"L Neckers","year":"1999","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0274364.ref029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yexcr.2005.03.003","article-title":"Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation","volume":"307","author":"BG Yun","year":"2005","journal-title":"Exp Cell Res"},{"issue":"1\u20132","key":"pone.0274364.ref030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11010-011-0977-0","article-title":"Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells","volume":"358","author":"A Wagatsuma","year":"2011","journal-title":"Mol Cell Biochem"},{"issue":"40","key":"pone.0274364.ref031","doi-asserted-by":"crossref","first-page":"26130","DOI":"10.18632\/oncotarget.25452","article-title":"Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity","volume":"9","author":"K Chai","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"pone.0274364.ref032","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1089\/gtmb.2021.0147","article-title":"Bioinformatic Analysis of Potential Biomarker for hsa-miR-196b-5p in Mesothelioma","volume":"25","author":"EJ Sohn","year":"2021","journal-title":"Genet Test Mol Biomarkers"},{"key":"pone.0274364.ref033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0703549","article-title":"Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo","volume":"131","author":"M Bucci","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"23","key":"pone.0274364.ref034","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"R Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"21","key":"pone.0274364.ref035","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen","volume":"120","author":"R Hassan","year":"2014","journal-title":"Cancer"},{"issue":"9","key":"pone.0274364.ref036","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"EL Servais","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"63","key":"pone.0274364.ref037","first-page":"1","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"X He","year":"2017","journal-title":"Mol Cancer"},{"issue":"15","key":"pone.0274364.ref038","article-title":"Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM)","volume":"32","author":"PA Zucali","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0274364.ref039","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BST20150252","article-title":"The role of the HGF\/Met axis in mesothelioma","volume":"44","author":"T Thayaparan","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"pone.0274364.ref040","article-title":"MEF2 transcription factors: developmental regulators and emerging cancer genes","volume":"7","author":"JR Pon","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0274364.ref041","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2011.02.008","article-title":"Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia","volume":"19","author":"I Homminga","year":"2011","journal-title":"Cancer Cell"},{"issue":"12","key":"pone.0274364.ref042","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2008-05-158196","article-title":"Homing and invasiveness of MLL\/ENL leukemic cells is regulated by MEF2C","volume":"114","author":"M Schwieger","year":"2009","journal-title":"Blood"},{"issue":"1","key":"pone.0274364.ref043","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00432-007-0252-7","article-title":"Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma","volume":"134","author":"X Bai","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"130","key":"pone.0274364.ref044","first-page":"1","article-title":"Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4\/ErbB2\/p38\/MEF2C-dependent mechanism","volume":"13","author":"JJ Zhang","year":"2014","journal-title":"Mol Cancer"},{"issue":"December 2014","key":"pone.0274364.ref045","first-page":"3","article-title":"Myocardin in biology and disease","volume":"29","author":"JM Miano","year":"2015","journal-title":"J Biomed Res"},{"issue":"3","key":"pone.0274364.ref046","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ncb1833","article-title":"Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis","volume":"11","author":"S Medjkane","year":"2009","journal-title":"Nat Cell Biol"},{"issue":"1882","key":"pone.0274364.ref047","first-page":"1","article-title":"Cytoskeletal dynamics in epithelial-mesenchymal transition: Insights into therapeutic targets for cancer metastasis","volume":"13","author":"A Datta","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0274364.ref048","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00284-005-0203-y","article-title":"Identification of AHBA biosynthetic genes related to geldanamycin biosynthesis in Streptomyces hygroscopicus 17997","volume":"52","author":"W He","year":"2006","journal-title":"Curr Microbiol"},{"issue":"1","key":"pone.0274364.ref049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-13-11","article-title":"Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines","volume":"13","author":"PK Karkoulis","year":"2013","journal-title":"Cancer Cell Int"},{"issue":"24","key":"pone.0274364.ref050","first-page":"1","article-title":"Structural basis for design of new purine-based inhibitors targeting the hydrophobic binding pocket of hsp90","volume":"21","author":"SC Shin","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0274364.ref051","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2009.07.010","article-title":"Geldanamycin and its anti-cancer activities","volume":"290","author":"Y Fukuyo","year":"2010","journal-title":"Cancer Lett"},{"issue":"4","key":"pone.0274364.ref052","doi-asserted-by":"crossref","first-page":"462","DOI":"10.15324\/kjcls.2018.50.4.462","article-title":"Cancer Chemoprevention Effects of Geldanamycin and 17-AAG in Human Oral Squamous Cell Carcinoma","volume":"50","author":"EJ Lee","year":"2018","journal-title":"Korean J Clin Lab Sci"},{"issue":"2","key":"pone.0274364.ref053","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.pcan.4500852","article-title":"Effects of geldanamycin on HIF-1\u03b1 mediated angiogenesis and invasion in prostate cancer cells","volume":"9","author":"O Alqawi","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"pone.0274364.ref054","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/JTO.0b013e3181839693","article-title":"Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma","volume":"3","author":"J Okamoto","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"pone.0274364.ref055","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(20)30424-1","article-title":"Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy","volume":"21","author":"AA Tran","year":"2020","journal-title":"Lancet Oncol"},{"issue":"January","key":"pone.0274364.ref056","first-page":"1","article-title":"Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics","volume":"10","author":"E Hern\u00e1ndez-Lemus","year":"2021","journal-title":"Front Oncol"},{"issue":"612","key":"pone.0274364.ref057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abd5524","article-title":"Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers","volume":"13","author":"CG Begley","year":"2021","journal-title":"Sci Transl Med"},{"issue":"10","key":"pone.0274364.ref058","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 Intratumoral Immunotherapy Enhances CD8 + T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2","volume":"171","author":"C Jackaman","year":"2003","journal-title":"J Immunol"},{"issue":"6","key":"pone.0274364.ref059","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a murine model of malignant mesothelioma","volume":"52","author":"MR Davis","year":"1992","journal-title":"Int J Cancer"},{"issue":"1","key":"pone.0274364.ref060","first-page":"1","article-title":"Neo-antigen specific T cell responses indicate the presence of metastases before imaging","volume":"9","author":"VS Fear","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0274364.ref061","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.2910470219","article-title":"Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions","volume":"47","author":"LS Manning","year":"1991","journal-title":"Int J Cancer"},{"issue":"1","key":"pone.0274364.ref062","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1165\/rcmb.2014-0017OC","article-title":"Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1-dependent mechanism","volume":"53","author":"SM Lansley","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"pone.0274364.ref063","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"NL Bray","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"pone.0274364.ref064","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/nar\/gks1147","article-title":"InnateDB: Systems biology of innate immunity and beyond\u2014Recent updates and continuing curation","volume":"41","author":"K Breuer","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"e52727","key":"pone.0274364.ref065","first-page":"1","article-title":"Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells","volume":"99","author":"S Horibata","year":"2015","journal-title":"J Vis Exp"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T13:25:10Z","timestamp":1683293110000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274364"}},"subtitle":[],"editor":[{"given":"Luka","family":"Brcic","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274364","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.29.505655","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}